Ongoing
BITAP – AI-Driven Peptide Immunotherapy for Precision Cancer Treatment
The BITAP (BioInformatic Therapy Address Peptides) project is a pioneering research and development effort by IMMUNEO Therapeutics, funded by the European Union and the State of Brandenburg under the ProFIT Brandenburg program.
This three-year initiative aims to develop an advanced bioinformatics and artificial intelligence platform that identifies and validates tumor-specific neoantigens to create personalized peptide-based immunotherapies. These immunizations are designed to precisely stimulate the patient’s immune system to recognize and destroy cancer cells while minimizing side effects on healthy tissue.
In addition to fully personalized therapies, the project also develops Pan-BITAP immunizations targeting common tumor antigens across patient groups, enabling cost-effective and rapid treatment options initially focused on pancreatic cancer.
The BITAP research is conducted in cooperation with the University Hospital Brandenburg an der Havel and the Medical School Brandenburg (MHB), strengthening regional biotechnology innovation and contributing to local job creation and infrastructure development.
This project exemplifies IMMUNEO’s commitment to advancing personalized, scalable, and clinically translatable cancer immunotherapies that integrate AI-powered tumor profiling with cutting-edge peptide technology.
This project is co-funded by the European Union and the State of Brandenburg.
Completed
In 2022, we launched the GENImmune project, funded by the Federal Ministry of Education and Research (BMBF). This initiative involves collaboration with industry partners, scientific institutions, and academic research groups.
GENImmune aims to develop a comprehensive approach and software leveraging artificial intelligence (AI), machine learning (ML), natural language processing (NLP), and computational modeling (CM) to enhance our understanding of host-pathogen interactions in infectious diseases. The project seeks to support clinically relevant applications, such as vaccine development and drug target identification.
Beyond infectious diseases, the proposed method for mathematically representing multicellular systems can be applied to other conditions with significant immunological components, including cancer and the interactions between tumors and the immune system.
One exemplary application of GENImmune is the optimization of an existing development program for variant-independent SARS-CoV-2 immunization, designed to avoid antibody-dependent enhancement.
Completed
In early 2021, we launched the ZIM partner project ADaPT-IT, in collaboration with the Munich-based IT company Biomax Technology AG and the Institute for Immunology and Cell Biology at the University of Tübingen.
The goal of this project is to develop an AI-powered analysis platform that enables the highly accurate identification of individual tumor epitopes (immunogenic tumor antigens). This platform aims to advance the development of highly effective, personalized cancer therapies within the realm of precision medicine. One of the primary focuses of the project is metastatic breast cancer in all its forms.
The project is funded by the Ministry for Economic Affairs and Energy (BMWi), based on a resolution by the German Bundestag.